HERON THERAPEUTICS, INC. /DE/ — Director's Dealing 2021

Sep 29, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2021-09-20

Reporting Person: Dissanaike Sharmila (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	6250	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$12.15	2031-09-20	Common Stock (37500)		Direct

Footnotes

F1: The shares were granted as restricted stock units which vest in 16 equal quarterly installments beginning three months after the date of grant (09/20/2021).

F2: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (09/20/2021).